242 related articles for article (PubMed ID: 30660828)
1. Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells.
Roberti M; Schipani F; Bagnolini G; Milano D; Giacomini E; Falchi F; Balboni A; Manerba M; Farabegoli F; De Franco F; Robertson J; Minucci S; Pallavicini I; Di Stefano G; Girotto S; Pellicciari R; Cavalli A
Eur J Med Chem; 2019 Mar; 165():80-92. PubMed ID: 30660828
[TBL] [Abstract][Full Text] [Related]
2. Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib.
Bagnolini G; Milano D; Manerba M; Schipani F; Ortega JA; Gioia D; Falchi F; Balboni A; Farabegoli F; De Franco F; Robertson J; Pellicciari R; Pallavicini I; Peri S; Minucci S; Girotto S; Di Stefano G; Roberti M; Cavalli A
J Med Chem; 2020 Mar; 63(5):2588-2619. PubMed ID: 32037829
[TBL] [Abstract][Full Text] [Related]
3. Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors.
Falchi F; Giacomini E; Masini T; Boutard N; Di Ianni L; Manerba M; Farabegoli F; Rossini L; Robertson J; Minucci S; Pallavicini I; Di Stefano G; Roberti M; Pellicciari R; Cavalli A
ACS Chem Biol; 2017 Oct; 12(10):2491-2497. PubMed ID: 28841282
[TBL] [Abstract][Full Text] [Related]
4. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
5. A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination.
Luo K; Li L; Li Y; Wu C; Yin Y; Chen Y; Deng M; Nowsheen S; Yuan J; Lou Z
Genes Dev; 2016 Dec; 30(23):2581-2595. PubMed ID: 27941124
[TBL] [Abstract][Full Text] [Related]
6. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
[TBL] [Abstract][Full Text] [Related]
7. A novel UCHL
Song Z; Tu X; Zhou Q; Huang J; Chen Y; Liu J; Lee S; Kim W; Nowsheen S; Luo K; Yuan J; Lou Z
Cell Death Dis; 2019 May; 10(6):398. PubMed ID: 31113933
[TBL] [Abstract][Full Text] [Related]
8. An
Myers SH; Poppi L; Rinaldi F; Veronesi M; Ciamarone A; Previtali V; Bagnolini G; Schipani F; Ortega Martínez JA; Girotto S; Di Stefano G; Farabegoli F; Walsh N; De Franco F; Roberti M; Cavalli A
Eur J Med Chem; 2024 Feb; 265():116114. PubMed ID: 38194775
[TBL] [Abstract][Full Text] [Related]
9. A Short BRCA2-Derived Cell-Penetrating Peptide Targets RAD51 Function and Confers Hypersensitivity toward PARP Inhibition.
Trenner A; Godau J; Sartori AA
Mol Cancer Ther; 2018 Jul; 17(7):1392-1404. PubMed ID: 29654063
[TBL] [Abstract][Full Text] [Related]
10. Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.
Lohse I; Kumareswaran R; Cao P; Pitcher B; Gallinger S; Bristow RG; Hedley DW
PLoS One; 2016; 11(12):e0167272. PubMed ID: 28033382
[TBL] [Abstract][Full Text] [Related]
11. New RAD51 Inhibitors to Target Homologous Recombination in Human Cells.
Shkundina IS; Gall AA; Dick A; Cocklin S; Mazin AV
Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34208492
[TBL] [Abstract][Full Text] [Related]
12. Preomic profile of BxPC-3 cells after treatment with BRC4.
Previtali V; Myers SH; Poppi L; Wynne K; Casamassima I; Girotto S; Di Stefano G; Farabegoli F; Roberti M; Oliviero G; Cavalli A
J Proteomics; 2023 Sep; 288():104983. PubMed ID: 37536521
[TBL] [Abstract][Full Text] [Related]
13. Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations.
Park PH; Yamamoto TM; Li H; Alcivar AL; Xia B; Wang Y; Bernhardy AJ; Turner KM; Kossenkov AV; Watson ZL; Behbakht K; Casadei S; Swisher EM; Mischel PS; Johnson N; Bitler BG
Mol Cancer Ther; 2020 Feb; 19(2):602-613. PubMed ID: 31575654
[TBL] [Abstract][Full Text] [Related]
14. Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
Guffanti F; Alvisi MF; Anastasia A; Ricci F; Chiappa M; Llop-Guevara A; Serra V; Fruscio R; Degasperi A; Nik-Zainal S; Bani MR; Lupia M; Giavazzi R; Rulli E; Damia G
Br J Cancer; 2022 Jan; 126(1):120-128. PubMed ID: 34732853
[TBL] [Abstract][Full Text] [Related]
15. Targeting DDX11 promotes PARP inhibitor sensitivity in hepatocellular carcinoma by attenuating BRCA2-RAD51 mediated homologous recombination.
Cao K; Wang R; Li L; Liao Y; Hu X; Li R; Liu X; Xiong XD; Wang Y; Liu X
Oncogene; 2024 Jan; 43(1):35-46. PubMed ID: 38007537
[TBL] [Abstract][Full Text] [Related]
16. Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Ji W; Weng X; Xu D; Cai S; Lou H; Ding L
Biochem Biophys Res Commun; 2020 Jan; 522(1):121-126. PubMed ID: 31753490
[TBL] [Abstract][Full Text] [Related]
17. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
18. BRCA2: one small step for DNA repair, one giant protein purified.
Jensen RB
Yale J Biol Med; 2013 Dec; 86(4):479-89. PubMed ID: 24348212
[TBL] [Abstract][Full Text] [Related]
19. Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
Zhong Q; Hu Z; Li Q; Yi T; Li J; Yang H
Gynecol Oncol; 2019 Jan; 152(1):157-165. PubMed ID: 30414739
[TBL] [Abstract][Full Text] [Related]
20. Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.
Wilson AJ; Sarfo-Kantanka K; Barrack T; Steck A; Saskowski J; Crispens MA; Khabele D
Gynecol Oncol; 2016 Oct; 143(1):143-151. PubMed ID: 27444036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
